Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.74 |
| ▸ | BCR | P11274 | 11/20 | 0.74 |
| ▸ | SRC | P12931 | 8/20 | 0.74 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | PRKACA | P17612 | 1/20 | 0.62 |
| ▸ | PRKACG | P22612 | 1/20 | 0.62 |
| ▸ | PRKACB | P22694 | 1/20 | 0.62 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.61 |
| ▸ | ABL2 | P42684 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.58 |
| ▸ | PRKCA | P17252 | 4/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | PRKCG | P05129 | 1/20 | 0.58 |
| ▸ | PRKCB | P05771 | 1/20 | 0.58 |
| ▸ | PRKCH | P24723 | 1/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442 | 0.85 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL4003048 | 0.84 | ABL1 (0.60) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2941787 | 0.83 | ABL1 (0.75) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL4002795 | 0.83 | GRM4 (0.53) | ABL1BCRSRCMAPK8JAK2 | |
| SCHEMBL823915 | 0.82 | CAMK2D (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL3087891 | 0.82 | GRM4 (0.70) | EGFR | |
| SCHEMBL4386919 | 0.81 | ABL1 (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL3012944 | 0.80 | ABL1 (0.70) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL14530851 | 0.79 | PLK1 (0.75) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL27444270 | 0.78 | PLK1 (0.78) | ABL1BCRSRCEGFRPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | claimed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | ABL1 131/4885BCR 35/4885SRC 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.